The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial - Wikidata - wikimedia - TriplyDB

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

http://www.wikidata.org/entity/Q35111527

about

The ancient drug salicylate directly activates AMP-activated protein kinase Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target Effects of NSAIDs on the risk factors of colorectal cancer: a mini review High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms Diabetic Cardiovascular Disease Induced by Oxidative Stress The role of fatty acids in insulin resistance The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: a systematic review and meta-analysis Targeting inflammation in diabetes: Newer therapeutic options Islet inflammation: a unifying target for diabetes treatment?Something old, something new and something very old: drugs for treating type 2 diabetes The outliers become a stampede as immunometabolism reaches a tipping point Regenerative therapies for diabetic microangiopathy Implication of inflammatory signaling pathways in obesity-induced insulin resistance Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior Obesity: An Immunometabolic Perspective Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization Salicylate prevents virus-induced type 1 diabetes in the BBDR rat Regulation of diet-induced adipose tissue and systemic inflammation by salicylates and pioglitazone Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance Inflammation-induced microvascular insulin resistance is an early event in diet-induced obesity Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study.Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study.A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects What causes the insulin resistance underlying obesity?AMPK activation--protean potential for boosting healthspan.Salsalate ameliorates metabolic disturbances by reducing inflammation in spontaneously hypertensive rats expressing human C-reactive protein and by activating brown adipose tissue in nontransgenic controls Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes.Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis.First anti-inflammatory generic drug promising new therapy for diabetes.Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study.Metabolic heterogeneity of obesity: role of adipose tissue.B lymphocytes as emerging mediators of insulin resistance.The effect of salsalate on biochemical factors and endothelial dysfunction of prediabetic patients: A randomized clinical trial Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.Anti-inflammatory therapies for cardiovascular disease An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.

P2860

Q24630758-D1C55558-0B74-4C72-A7C7-19F4172C16A8 Q26741391-69B96F57-6067-412E-8606-BDE0DC66BB32 Q26746884-C4C89566-69D1-433E-9D6C-5821BB347527 Q26774658-C2290567-4339-4CB0-A797-C830CF8A1BAC Q26778017-E36461D3-5F93-4476-BA88-2B0109A31DAD Q26785440-0C9D5116-98F0-4118-892B-ABAC649D728E Q26822372-FEE8E2FB-94E9-49B0-85B0-A9CD094141C1 Q26852726-59320A98-B89D-4F02-ACA0-BF7683E22389 Q26860847-A4BE5582-E872-47A8-AD4F-ABB87E30B6A8 Q26865663-DD12361F-3BFB-4397-8071-E44140F36ED5 Q27005951-978D054E-A7F9-42DD-805A-631B29B2B78F Q27027852-E39C0582-DF19-4D97-AF4D-FDFC55675037 Q27500365-2D57B128-BC0E-4EEB-959F-FD267BFE4855 Q27694728-9131B32A-F169-4C33-B4FA-4BCE6C31D157 Q28072140-0A6E9973-8681-45DC-A026-7829A59EC4A0 Q28260504-FADEECEA-5745-47CC-A6B2-33D2BBAA5F04 Q28534436-24628ACA-D644-48CB-9240-300BAEF98FF6 Q28537905-5D3924E9-EC8A-4895-9E52-8DC16913274B Q28831354-6D842CE9-68C5-4901-8DAA-CA15B2CEE0C3 Q30009848-4BBB8E38-8FD3-4C4A-BD12-A81215CF7005 Q30278865-19552CB8-66A8-4DF2-9FBE-F364CCD5720F Q30426185-B499F09F-D324-46E0-AA1E-7C69FE753ED6 Q30426407-45F69B7F-8E0A-47EF-AEA5-112D77E318D4 Q33585792-0A8D474F-40BA-458A-8550-7D4C8C8562FE Q33624371-BBE49A98-FDC3-4020-A0C4-0543EE340FB5 Q33625958-BF8D04D8-1915-47C3-84CC-B305CE863ADC Q33684984-6BE31EE8-3486-4395-BFB3-A72CC3D3AB9B Q33689169-4FD63559-A2B6-46F7-853E-D5F0A4D95014 Q33769258-64EBFAB2-B3B7-4864-B46F-54C8DC799EAA Q33862296-A90AC09B-E4C7-4748-B6BE-13621D092AB8 Q33909300-ACCF7981-BA8B-419C-9F5E-4A4F1C8CDD86 Q33932051-931B55A6-7805-4D9B-AB25-CC3A1B09968F Q33932928-001EDC26-98D9-4646-A62E-EBB4E57BB4AC Q33942543-07962E7F-DA40-45FD-AB0B-E89E63BB5F0E Q33942560-2304B36A-36D1-4850-888B-0DD880684306 Q33970976-24C3F792-E5C0-4C2C-8C0A-AFB0D292187A Q34027442-95266614-91CE-48F6-BD0D-E6D55DF25712 Q34137872-B556096F-F0D6-43E5-AAAC-345F325CD53B Q34327061-618E803E-DCB6-4E17-BC7B-3295BAD39E03 Q34444895-D8D8B5B8-B268-47D2-96D8-A278D4EC36FD

P2860

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

http://www.wikidata.org/entity/Q35111527

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@ast

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@en

type

label

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@ast

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@en

prefLabel

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@ast

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@en

P1433

Q35111527-C64DDDBD-79AA-4CB2-B520-778FE4D71EF2

P1476

Q35111527-192028C9-E477-4B04-89E4-3F2910B5E59C

P2093

Q35111527-38FD73B3-3737-47CB-8CF3-6DBB5B438CFC

Q35111527-49ABC64E-F209-4341-9E7C-8404EE54952C

Q35111527-5C029CCE-7607-4A06-9DD9-B04EB67B0F7F

Q35111527-7D64092F-3C3B-4248-8232-B6B9C2B6B7E3

Q35111527-9B2CBC24-6D64-4750-9AA6-9E79F1377945

Q35111527-CA39CA26-321F-40D6-A87E-9C8C513DABEA

Q35111527-E3616E6A-47AC-4430-AC10-82510CF8D73E

P2860

Q35111527-0363BBC1-DA65-4024-86F4-1938AC0D903F

Q35111527-07C79DD0-8E7F-4A5F-89C4-5718F2CC3320

Q35111527-07E369D3-C7E0-44EE-B61F-C21D4D0DAC18

Q35111527-0A0F586C-6302-432C-A208-C702CE0ED611

Q35111527-0E37AFF8-CBB5-452F-BDA5-9671FED73408

Q35111527-0F959ECE-E432-426A-B755-2404BF065166

Q35111527-11B6A9F5-8F91-484E-A660-C06FC9F9BB7A

Q35111527-235EE604-BF21-4715-88C5-82D5DDD5678B

Q35111527-29809958-2A1E-4B44-B0DD-18FB8A9F9B30

Q35111527-2ED258FB-55CA-481E-A4F3-5F1E0C4BFD0C

P304

Q35111527-13B36F00-6667-4116-B5D5-BD6C8713E1D8

P31

Q35111527-781DBF42-2FF0-441D-A4DA-6A99F2D04598

P356

Q35111527-BFEF78F7-241D-44E7-AF21-57411A309793

P407

Q35111527-AA544B94-FB7F-4100-92AB-A05AE9389455

P433

Q35111527-4AA63D6D-DD64-4E6E-8963-A0EDB9904D16

P478

Q35111527-D72CD6F0-6E71-4F8F-89F2-0FECA520C696

P577

Q35111527-618DFFCE-B2F5-4734-AA2E-0F8B3760998F

P698

Q35111527-27B69980-1BA6-485E-8983-A68748C8756C

P921

Q35111527-8C9553AE-7099-48B0-8FB6-BF0F80A1FB70

Q35111527-935A1386-5853-47A4-8D09-84207B266B04

P932

Q35111527-571C5053-A20C-4909-AD48-151A60B10F37

P356

0003-4819-152-6-201003160-00004

P1433

Annals of Internal Medicine

P1476

The effects of salsalate on gl ...... 2 diabetes: a randomized trial

@en

P2093

Allison B Goldfine

http://www.w3.org/2001/XMLSchema#string

Kathleen A Jablonski

http://www.w3.org/2001/XMLSchema#string

Laura Pyle

http://www.w3.org/2001/XMLSchema#string

Myrlene A Staten

http://www.w3.org/2001/XMLSchema#string

Steven E Shoelson

http://www.w3.org/2001/XMLSchema#string

TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team

http://www.w3.org/2001/XMLSchema#string

Vivian Fonseca

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and insulin resistance

Variations in DNA elucidate molecular networks that cause disease

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

Inflammation and metabolic disorders

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

IKK-beta links inflammation to obesity-induced insulin resistance

Inhibition of NF-kappa B by sodium salicylate and aspirin

The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

P304

346-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-152-6-201003160-00004

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

152

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20231565

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3138470

http://www.w3.org/2001/XMLSchema#string